(CTXR) Citius Pharmaceuticals - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US17322U2078
CTXR: Immunotherapy, Antibiotic, Topical Formulation, Catheter Solution
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is a biopharmaceutical company specializing in the development and commercialization of critical care and oncology products. The companys lead approved product, LYMPHIR, is an FDA-cleared immunotherapy designed for the treatment of cutaneous T-cell lymphoma (CTCL). Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution currently in Phase 3 trials for the salvage of infected central venous catheters in patients with catheter-related bloodstream infections (CRBSIs), and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids, which has completed Phase 2b trials. The company was established in 2007 and operates from its headquarters in Cranford, New Jersey. For more information, visit https://citiuspharma.com.
Exchange: NASDAQ
Type: common stock
Country Origin: United States
GICS Sub Industry: Pharmaceuticals
Last Price: 1.79
SMA 20: 2.05
SMA 50: 2.80
SMA 200: 10.39
ATR: 0.27
P/E: 0.00
P/E Forward: 9.13
P/B: 0.22
P/S: 0.00
RoE: -60.66
Based on the analysis of
Additional Sources for CTXR Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CTXR Stock Overview
Market Cap in USD | 14m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2017-07-06 |
CTXR Stock Ratings
Growth 5y | -83.7% |
Fundamental | - |
Dividend | 0.0% |
Rel. Strength Industry | -91.4 |
Analysts | 4.33/5 |
Fair Price Momentum | 1.17 USD |
Fair Price DCF | - |
CTXR Dividends
No Dividends PaidCTXR Growth Ratios
Growth Correlation 3m | -74.4% |
Growth Correlation 12m | -92% |
Growth Correlation 5y | -60.7% |
CAGR 5y | -34.52% |
CAGR/Max DD 5y | -0.35 |
Sharpe Ratio 12m | -2.61 |
Alpha | -103.18 |
Beta | 1.18 |
Volatility | 81.49% |
Current Volume | 47.1k |
Average Volume 20d | 82.3k |
As of March 15, 2025, the stock is trading at USD 1.50 with a total of 47,077 shares traded.
Over the past week, the price has changed by -16.20%, over one month by -44.24%, over three months by -41.86% and over the past year by -91.29%.
No, based on ValueRay Analyses, Citius Pharmaceuticals (NASDAQ:CTXR) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -83.69 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CTXR as of March 2025 is 1.17. This means that CTXR is currently overvalued and has a potential downside of -22%.
Citius Pharmaceuticals has received a consensus analysts rating of 4.33. Therefor, it is recommend to buy CTXR.
- Strong Buy: 1
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, CTXR Citius Pharmaceuticals will be worth about 1.3 in March 2026. The stock is currently trading at 1.50. This means that the stock has a potential downside of -13.33%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 39 | 2500% |
Analysts Target Price | 4.7 | 211.3% |
ValueRay Target Price | 1.3 | -13.3% |